Immunopathogenesis and immunotherapeutic approaches to type 1A diabetes

Bibliography

• EISENBARTH GS: Prediction of type 1 diabetes: the natural history of the prediabetic period. In: Type I Diabetes: Molecular, Cellular and Clinical ImmunologyEisenbarth GS, Lafferty KJ (Eds), Oxford University Press, New York, USA (1996):230–258.
   Google Scholar
• FOULIS AK, LIDDLE CN,FARQUHARSON MA, RICHMOND JA, WEIR RS: The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia (1986) 29(5):267–274.
   PubMed Web of Science ®Google Scholar
• KELEMAN K: The role of T cells in beta cell damage in NOD mice and humans. In: Type I Diabetes: Molecular, Cellular and Clinical Immunology Eisenbarth GS, Lafferty KJ (Eds), Oxford University Press, New York, USA (1996). (Can be accessed at www.barbaradaviscenter.org).
   Google Scholar
• PALMER JP, FLEMING GA et al.: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA Workshop, 21-22 October 2001. Diabetes (2004) 53(1):250–264.
   PubMedGoogle Scholar
• EISENBARTH GS, MORIYAMA H et al.: Insulin autoimmunity: prediction/ precipitation/prevention type 1A diabetes. AutoimmuniOt Rev (2002) 1:139–145.
   PubMedGoogle Scholar
• FAIN P, EISENBARTH G: Type 1 diabetes, autoimmunity, and the MHC. In: Genetics of Diabetes Mellitus. Lowe WL (Ed.), Kluwer Academic Publishers, Boston/Dordrecht/ London (2000):43–64.
   Google Scholar
• FAIN P, EISENBARTH G: Genetics of type 1 diabetes mellitus. In: Genetics in Endocrinology Baxter J, Melmed S, New M, Martini L (Eds), Lippincott Williams & Williams, Philadelphia, USA (2002):37–72.
   Google Scholar
• DEVENDRA D, LIU E,EISENBARTH GS: Type 1 diabetes: recent developments. Br. Med. J. (2004) 328(7442):750–754.
   PubMed Web of Science ®Google Scholar
• ATKINSON MA, EISENBARTH GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (2001) 358(9277):221–229.
   PubMed Web of Science ®Google Scholar
• PUGLIESE A: Peripheral antigen-expressing cells and autoimmunity. Endocrinol. Metab. Clin. North Am. (2002) 31(2):411–430, viii.
   Google Scholar
• BOTTINI N, MUSCUMECI L et al.: A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. (2004) 36:337–338.
   PubMed Web of Science ®Google Scholar
• ••Autoirnmunity gene polymorphism.
   Google Scholar
• BEGOVICH AB, CARLTON VE, HONIGBERG LA et al.: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.Hum. Genet. (2004) 75(2):330–337.
   Google Scholar
• HYOTY H: Environmental causes: viral causes. Endocrinol. Metab. Clin. North Am. (2004) 33(1):27–44, viii.
   Google Scholar
• NORRIS JM, BARRIGA K et al.: Timing of cereal exposure in infancy and risk of islet autoimmunity. The Diabetes Autoimmunity Study in the Young (DAISY). JAMA (2003) 290:1713–1720.
   Google Scholar
• ZIEGLER AG, SCHMID S, HUBER D, HUMMEL M, BONIFACIO E: Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA (2003) 290(13):1721–1728.
   PubMed Web of Science ®Google Scholar
• YU L, EISENBARTH GS: Humoral autoimmunity. In: Type I Diabetes: Cellular, Molecular and Clinical ImmunologyEisenbarth GS, Lafferty KJ (Eds), Oxford University Press, New York, USA (1996):209–229.
   Google Scholar
• VERGE CF, STENGER D et al.: Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes (1998) 47(12):1857–1866.
   PubMed Web of Science ®Google Scholar
• MUELLER PW, BINGLEY PJ, BONIFACIO E, STEINBERG KK, SAMPSON EJ: Predicting type 1 diabetes using autoantibodies: the latest results from the diabetes autoantibody standardizationprogram. Diabetes Technol. Titer (2002) 4(3)397–400.
   Google Scholar
• VERGE CF, GIANANI R et al.: Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes (1996) 45(7):926–933.
   PubMed Web of Science ®Google Scholar
• ••Illustrates high predictability withmultiple antibodies.
   Google Scholar
• BINGLEY PJ, BONIFACIO E et al.: Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes (1997) 46:1701–1710.
   PubMed Web of Science ®Google Scholar
• MCHUGH RS, SHEVACH EM: Cutting edge: depletion of CD4(+)CD25(+) regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. Immunol. (2002) 168 (12):5979–5983.
   Web of Science ®Google Scholar
• FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol (2003) 4(4)330–336.
   Google Scholar
• SMYK-PEARSON SK, BAKKE AC, HELD PK, WILDIN RS: Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin. Exp. Immunol. (2003) 133(2):193–199.
   PubMed Web of Science ®Google Scholar
• ALLEN HF, KLINGENSMITH GJ et al.: Effect of BCG vaccination on new-onset insulin-dependent diabetes mellitus: a randomized clinical study. Diabetes Care (1998) 22(10):1703–1707.
   Web of Science ®Google Scholar
• MORIYAMA H, ABIRU N et al.: Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the NOD mouse. Proc. Nati Acad. Sri. USA (2003) 100(18):10376–10381.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Prevention Trial - Type 1 Diabetes Study Group. N Engl. J. Med. (2002) 346(22):1685–1691.
   Google Scholar
• GREENBAUM CJ, HARRISON LC: Guidelines for intervention trials in subjectsExpert Op/n. Biol. Ther. (2004) 4(10) with newly diagnosed type 1 diabetes. Diabetes (2003) 52(5):1059–1065.
   Google Scholar
• ASSAN R, BLANCHET F et al: Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab. Res. Rev (2002) 18(6):464–472.
   PubMed Web of Science ®Google Scholar
• HEROLD KC, HAGOPIAN W et al: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl. Med. (2002) 346(22):1692–1698.
   PubMed Web of Science ®Google Scholar
• ••Exciting clinical trial.
   Google Scholar
• BELGHITH M, BLUESTONE JA et al.: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. (2003) 9(9):1202–1208.
   PubMed Web of Science ®Google Scholar
• ALLEVA DG, GAUR A et al: Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes (2002) 51(7):2126–2134.
   PubMed Web of Science ®Google Scholar
• PAZ I, ELIAS D et al.: Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shockprotein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet (2001) 358(9295):1749–1753.
   PubMed Web of Science ®Google Scholar
• BOWMAN M, ATKINSON MA: Heat shock protein therapy fails to prevent diabetes in NOD mice. Diabetologia (2002) 45(9):1350–1351.
   PubMed Web of Science ®Google Scholar
• RYAN EA, LAKEY JR et al.: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 51(7):2148–2157.
   PubMed Web of Science ®Google Scholar
• HIRSHBERG B, ROTHER KI et aL: Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care (2003) 26(12):3288–3295.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP: Islet transplantation as a treatment for diabetes — a work in progress. N Engl. I Med. (2004) 350(7):694–705.
   PubMed Web of Science ®Google Scholar
• ROBERTSON RP: Consequences on beta-cell function and reserve after long-term pancreas transplantation. Diabetes (2004) 53(3):633–644.
   PubMed Web of Science ®Google Scholar
• WILDIN RS, SMYK-PEARSON S, FILIPOVICH AH: Clinical and molecularfeatures of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. Med. Genet. (2002) 39(8):537–545.
   PubMed Web of Science ®Google Scholar
• PATEL DD: Escape from tolerance in thehuman X-linked autoimmunity-allergic disregulation syndrome and the Scurfy mouse. J. Clin. Invest. (2001) 107(2):155–157.
   PubMed Web of Science ®Google Scholar
• http://www.barbaradaviscenter.org Barbara Davis Center for Childhood Diabetes.
   Google Scholar
• ••Detailed web book on immunology oftype I diabetes, with teaching slides.
   Google Scholar
• http://www.immunetolerance.org Immune Tolerance Network (ITN).
   Google Scholar
• http://www.diabetestrialnet.com TrialNet.
   Google Scholar